TRADES
Latest Trades
FUND
DATE
ACTION
TICKER
COMPANY
SHARES
% of ETF
ARKX 20 Apr 2022 Buy GOOG ALPHABET INC 221 0.1434
ARKX 20 Apr 2022 Sell AVAV AEROVIRONMENT INC 2,276 0.0581
ARKX 20 Apr 2022 Sell ESLT ELBIT SYSTEMS LTD 534 0.0299
ARKF 19 Apr 2022 Sell LC LENDINGCLUB CORP 232,643 0.2454
ARKF 19 Apr 2022 Sell ETSY ETSY INC 21,463 0.1863
ARKF 19 Apr 2022 Buy NU NU HOLDINGS LTD/CAYMAN ISLANDS 339,626 0.1795
ARKF 19 Apr 2022 Buy GLBE GLOBAL-E ONLINE LTD 53,810 0.1162
ARKG 19 Apr 2022 Sell CSTL CASTLE BIOSCIENCES INC 470,115 0.3516
ARKG 19 Apr 2022 Buy MASS 908 DEVICES INC 13,263 0.0079
ARKG 19 Apr 2022 Buy QSI QUANTUM-SI INC 57,858 0.0076
ARKG 19 Apr 2022 Buy PSNL PERSONALIS INC 20,000 0.0042
ARKG 19 Apr 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 68 0.0000
ARKK 19 Apr 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 123 0.0000
ARKQ 19 Apr 2022 Buy VLD VELO3D INC 619,269 0.1955
ARKQ 19 Apr 2022 Sell AVAV AEROVIRONMENT INC 15,565 0.1089
ARKQ 19 Apr 2022 Sell ESLT ELBIT SYSTEMS LTD 1,197 0.0174
ARKW 19 Apr 2022 Sell TWTR TWITTER INC 114,576 0.2506
ARKW 19 Apr 2022 Buy TWLO TWILIO INC 20,750 0.1337
ARKX 19 Apr 2022 Buy VLD VELO3D INC 162,774 0.1971
ARKX 19 Apr 2022 Sell AVAV AEROVIRONMENT INC 4,102 0.1101
ARKX 19 Apr 2022 Buy GOOG ALPHABET INC 100 0.0651
ARKX 19 Apr 2022 Sell ESLT ELBIT SYSTEMS LTD 212 0.0118
ARKG 18 Apr 2022 Sell CSTL CASTLE BIOSCIENCES INC 50,697 0.0373
ARKG 18 Apr 2022 Buy QSI QUANTUM-SI INC 39,726 0.0050
ARKG 18 Apr 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 31,528 0.0034
ARKG 18 Apr 2022 Buy PSNL PERSONALIS INC 15,000 0.0030
ARKG 18 Apr 2022 Buy MASS 908 DEVICES INC 1,846 0.0011
ARKK 18 Apr 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 602,754 0.0200
ARKG 14 Apr 2022 Buy NTLA INTELLIA THERAPEUTICS INC 13,763 0.0248
ARKG 14 Apr 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 173,826 0.0195
ARKG 14 Apr 2022 Buy BEAM BEAM THERAPEUTICS INC 13,409 0.0193
ARKK 14 Apr 2022 Buy NTLA INTELLIA THERAPEUTICS INC 43,968 0.0243
ARKK 14 Apr 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 619,872 0.0214
ARKK 14 Apr 2022 Buy BEAM BEAM THERAPEUTICS INC 38,691 0.0171
ARKK 14 Apr 2022 Buy SSYS STRATASYS LTD 15,114 0.0029
ARKK 14 Apr 2022 Buy TWOU 2U INC 10,052 0.0011
ARKQ 14 Apr 2022 Buy SSYS STRATASYS LTD 3,270 0.0046
ARKQ 14 Apr 2022 Buy TWOU 2U INC 1,240 0.0010
ARKW 14 Apr 2022 Buy TWOU 2U INC 2,056 0.0012
ARKF 13 Apr 2022 Sell LC LENDINGCLUB CORP 29,543 0.0305
ARKG 13 Apr 2022 Sell VRTX VERTEX PHARMACEUTICALS INC 11,746 0.1000
ARKG 13 Apr 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 361,847 0.0405
ARKG 13 Apr 2022 Buy MASS 908 DEVICES INC 11,744 0.0067
ARKG 13 Apr 2022 Buy BEAM BEAM THERAPEUTICS INC 2,574 0.0038
ARKG 13 Apr 2022 Buy NTLA INTELLIA THERAPEUTICS INC 1,109 0.0020
ARKG 13 Apr 2022 Buy QSI QUANTUM-SI INC 15,000 0.0019
ARKG 13 Apr 2022 Buy PSNL PERSONALIS INC 6,854 0.0015
ARKK 13 Apr 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 1,190,284 0.0419
ARKK 13 Apr 2022 Buy BEAM BEAM THERAPEUTICS INC 7,426 0.0035
ARKK 13 Apr 2022 Buy NTLA INTELLIA THERAPEUTICS INC 3,543 0.0020
ARKK 13 Apr 2022 Buy SSYS STRATASYS LTD 3,287 0.0007
ARKQ 13 Apr 2022 Buy SSYS STRATASYS LTD 711 0.0010
ARKX 13 Apr 2022 Buy BLDE BLADE AIR MOBILITY INC 10,567 0.0236
ARKF 12 Apr 2022 Sell LC LENDINGCLUB CORP 122,897 0.1250
ARKF 12 Apr 2022 Buy PATH UIPATH INC 67,417 0.0992
ARKG 12 Apr 2022 Buy MASS 908 DEVICES INC 100,007 0.0585
ARKG 12 Apr 2022 Buy PSNL PERSONALIS INC 119,876 0.0266
ARKG 12 Apr 2022 Sell CSTL CASTLE BIOSCIENCES INC 15,097 0.0132
ARKG 12 Apr 2022 Buy NTLA INTELLIA THERAPEUTICS INC 5,691 0.0104
ARKG 12 Apr 2022 Buy NVTA INVITAE CORP 18,874 0.0039
ARKG 12 Apr 2022 Buy QSI QUANTUM-SI INC 15,000 0.0019
ARKK 12 Apr 2022 Buy NTLA INTELLIA THERAPEUTICS INC 18,178 0.0105
ARKK 12 Apr 2022 Buy SSYS STRATASYS LTD 41,831 0.0086
ARKK 12 Apr 2022 Buy NVTA INVITAE CORP 57,427 0.0038
ARKQ 12 Apr 2022 Buy SSYS STRATASYS LTD 9,049 0.0128
ARKX 12 Apr 2022 Buy BLDE BLADE AIR MOBILITY INC 10,089 0.0211
ARKF 11 Apr 2022 Buy PATH UIPATH INC 202,721 0.2926
ARKF 11 Apr 2022 Sell LC LENDINGCLUB CORP 235,347 0.2388
ARKG 11 Apr 2022 Sell CSTL CASTLE BIOSCIENCES INC 58,145 0.0526
ARKG 11 Apr 2022 Buy MASS 908 DEVICES INC 62,313 0.0350
ARKG 11 Apr 2022 Buy PSNL PERSONALIS INC 65,932 0.0141
ARKG 11 Apr 2022 Buy QSI QUANTUM-SI INC 66,118 0.0079
ARKG 11 Apr 2022 Buy NTLA INTELLIA THERAPEUTICS INC 4,138 0.0074
ARKG 11 Apr 2022 Buy BEAM BEAM THERAPEUTICS INC 4,416 0.0061
ARKG 11 Apr 2022 Buy NVTA INVITAE CORP 19,893 0.0040
ARKK 11 Apr 2022 Buy NTLA INTELLIA THERAPEUTICS INC 13,007 0.0074
ARKK 11 Apr 2022 Buy BEAM BEAM THERAPEUTICS INC 12,538 0.0055
ARKK 11 Apr 2022 Buy NVTA INVITAE CORP 59,559 0.0038
ARKK 11 Apr 2022 Buy SSYS STRATASYS LTD 17,181 0.0034
ARKK 11 Apr 2022 Buy TWOU 2U INC 5,655 0.0006
ARKQ 11 Apr 2022 Buy SSYS STRATASYS LTD 3,764 0.0053
ARKQ 11 Apr 2022 Buy TWOU 2U INC 726 0.0006
ARKW 11 Apr 2022 Buy ROKU ROKU INC 76,603 0.4029
ARKW 11 Apr 2022 Sell TWTR TWITTER INC 185,900 0.3955
ARKW 11 Apr 2022 Buy TWOU 2U INC 1,201 0.0007
ARKX 11 Apr 2022 Buy BLDE BLADE AIR MOBILITY INC 30,990 0.0628
ARKG 7 Apr 2022 Buy NVTA INVITAE CORP 87,983 0.0181
ARKK 7 Apr 2022 Buy NVTA INVITAE CORP 266,206 0.0171
ARKQ 6 Apr 2022 Buy VLD VELO3D INC 14,150 0.0060
ARKX 6 Apr 2022 Buy VLD VELO3D INC 4,986 0.0083
ARKG 5 Apr 2022 Buy TWST TWIST BIOSCIENCE CORP 53,040 0.0730
ARKG 5 Apr 2022 Buy NRIX NURIX THERAPEUTICS INC 99,604 0.0377
ARKK 5 Apr 2022 Buy TWST TWIST BIOSCIENCE CORP 175,701 0.0735
ARKG 4 Apr 2022 Buy NRIX NURIX THERAPEUTICS INC 311,273 0.1167
ARKG 4 Apr 2022 Buy TWST TWIST BIOSCIENCE CORP 1,712 0.0024
ARKK 4 Apr 2022 Buy PATH UIPATH INC 867,331 0.1619
ARKK 4 Apr 2022 Buy TWST TWIST BIOSCIENCE CORP 5,545 0.0024
ARKX 4 Apr 2022 Buy MYNA MYNARIC AG 1,060 0.0028
ARKG 1 Apr 2022 Buy SLGC SOMALOGIC INC 242,467 0.0523
ARKG 1 Apr 2022 Buy TWST TWIST BIOSCIENCE CORP 6,920 0.0094
Latest Blogs
ARK by Cathie Wood is still suffering a year after its apex.

Cathie Wood's flagship exchange-traded fund hit an all-time high in February of this year. Her preferred disruptive-tech chasing strategy may still be in for a lot of suffering after a year and a 53 percent fall.

After a dramatic decline last month, the ARK Innovation ETF (ticker: ARKK) has steadied off - it's practically flat in February – but the headwinds surrounding its speculative growth picks are just becoming more vital. Many businesses that thrived during the pandemic are being hammered by the economic reopening, not only because yields are rising as investors prepare for the US Federal Reserve to raise interest rates, which is terrible news for unprofitable businesses, but also because the economic reopening is hammering many of the businesses that thrived during the pandemic.

Roku, Teladoc, and Zoom, all winners in the work-from-home era, have had their stock prices plummet by as much as 74% in the past year.

Short bets against ARK, according to IHS Markit data, hit a fresh high of 11.4 percent of outstanding shares this week. The Tuttle Capital Short Innovation ETF (SARK), which beats the ARK, now has assets worth more than $US300 million ($416 million).

"Those equities are supported by speculation, and speculation pays less well when the Fed raises rates," said Brent Schutte, chief investment strategist at Northwestern Mutual Wealth Management Co. "Much of what's happening in the market reminds me of what happened in the late 1990s when market segments were bid up to levels based on future assumptions."

Because its price chart resembles that of the Nasdaq index of technology businesses from more than two decades ago, analogies to that period and the dot-com implosion that followed are becoming more common in discussions of ARK.

"Today marks the 253rd trading day from ARK's all-time high," Jessica Rabe, co-founder of DataTrek Research, wrote in a Tuesday note, "while the Nasdaq was down 60% from its dot-com bubble top on the same day in 2001."

"If 2000/2001 analog holds, we should see ARK continuing to fall over the following three weeks. The Nasdaq dropped 18.7% in the next 16 trading days "recent."

Net flows are positive.

The better news for investors and Ms. Wood is that there may be some immediate respite. The Nasdaq rose 41% in six weeks in 2001 before falling.

The ARK Investment Management did not respond to a request for comment.

Most of ARK's $US15 billion asset loss has been attributed to bad performance, a plus for the company. Since the fund achieved an intraday high of $US159.70 a year ago this week, investors have withdrawn only around $US465 million, and ARK's net flows this year are positive despite a more than 20% drop.

This exceptional loyalty prevents a worsening situation and allows Wood's approach to recovering. The star fund manager has consistently emphasized that her funds have a five-year investment horizon and that she believes in many good options.

Mr. Schutte, on the other hand, says the drop is understandable because several of the company's biggest bets, such as Teladoc and Zoom, are becoming less significant as COVID-19 approaches.

"During the pandemic, there were a lot of questions about what would happen to society and how we'd go about our lives," he added.

"You drew in new investors who wanted to know "what are the upcoming themes I should invest in?" I believe you got a washout of it as well."

On Friday, Cathie Wood sold $148.9 million worth of Palantir stock, halving her exposure.

Ark Investment Management, run by Cathie Wood, sold more Palantir Technologies Inc PLTR -6.39 percent shares on Friday, cutting its stake in the Peter Thiel-backed company.

According to Friday's closing price, the famous investment management firm sold 13.5 million shares of the big data company, valued at $148.9 million.

Palantir's stock fell 6.4 percent to $11.02 per share on Friday. The stock has lost 16% of its value in the last week.

Before Friday's trade, Ark Invest held 25.53 million shares in Palantir, suggesting that the famous stock picker had trimmed over 52 percent of its total keeping a day later.

After the business disclosed lower-than-expected fourth-quarter earnings before the market opened on Thursday, Ark Invest, located in St. Petersburg, California, dumped shares in Palantir for the second time.

The software firm, well-known for its work with government organizations, posted earnings of 2 cents per share, falling short of the analyst consensus of 4 cents. The company recorded quarterly revenues of $432.87 million, higher than the $417.69 million predicted by analysts.

Palantir's stock had been sold for 4.77 million shares by the investment firm the day before.

All six of Ark Invest's active exchange-traded funds own Palantir stock, including the flagship Ark Innovation ETF ARKK -4.88 percent.

Before the recent sell-off, Ark Invest had been stockpiling Palantir shares for months.

Cathie Wood appeared on television to defend her ARK funds' dismal performance. It didn't go quite as planned.

The Ark Innovation ETF (ARKK), Cathie Wood's flagship fund, is down 30% year to date and more volatile than almost any other fund on the market. On CNBC's Halftime Report, Wood jumped at the chance to defend the fund and its deflated price, which is currently $68.80, down from $155 a year ago.

"We've seen a significant decline," Wood said, adding, "We feel innovation is at bargain basement zone." Even though her ETF was underperforming, she emphasized that her companies were still "very inexpensive" and that the current fund loss was temporary. When the call's 40 free minutes were finished, Zoom gave her an extra 10 minutes to complete the interview.

Having Zoom check to see whether she was "running out of time?" Wood, who has been aggressively buying up shares in Zoom and other IT firms that have fallen from their pandemic highs, was unhappy. Zoom, like Wood's other significant tech holdings, Teladoc Health, Roku, and Roblox, is down 20% to 40% year to date as investors worry about rising interest and inflation rates.

However, a significant chunk of the interview was devoted to a personal assault on Cathie Wood, who was named the most excellent stock picker in 2020 by Bloomberg's then-Editor-in-Chief Matthew Winkler after correctly forecasting that Tesla will one day be valued at more than $1 trillion.

Wood bluntly ignored Tuttle Capital Management's Short Innovation ETF (SARK), which tracks the inverse performance of ARKK using swaps contracts for the sole purpose of betting against Cathie Wood's selections. "They're not conducting any research." She explained, "All they're doing is shorting innovation."

Of course, SARK is betting against Cathie Woods, not on innovation. "Well, we stand for invention," Wood responded. The SARK ETF has gained 55 percent since its debut, whereas the ARKK ETF has declined by 42 percent.

Tuttle Capital Management CEO Matthew Tuttle chimed in on the SARK ETF, calling it a "tool" for investors. According to SARK, "to convey a negative view of the market, innovative enterprises, the current rising rate environment, or a [specific] portfolio manager if they wish." "It's un-American not to have options in the marketplace," Tuttle told Insider on Thursday.

In any event, Wood is making progress. Her main concern currently is bearish calls on her ETF. "Our major concern is that our investors convert temporary losses into long-term losses," Wood continued.